Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma

[1]  Carsten Wiuf,et al.  Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.

[2]  D. Jäger,et al.  Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors , 2011, International journal of cancer.

[3]  M. Zago,et al.  BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients , 2011, Oncogene.

[4]  R. Vessella,et al.  Expression of cancer/testis antigens in prostate cancer is associated with disease progression , 2010, The Prostate.

[5]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[6]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[7]  L. Lacombe,et al.  High frequency of MAGE‐A4 and MAGE‐A9 expression in high‐risk bladder cancer , 2009, International journal of cancer.

[8]  G. Schuler,et al.  The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. , 2009, Cancer research.

[9]  Marcos González,et al.  The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia , 2008, Haematologica.

[10]  A. Hart,et al.  PRAME expression and clinical outcome of breast cancer , 2008, British Journal of Cancer.

[11]  T. Griffith,et al.  Role of neutrophils in BCG immunotherapy for bladder cancer. , 2008, Urologic oncology.

[12]  K. Odunsi,et al.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[13]  A. Bergeron,et al.  MAGE‐A9 mRNA and protein expression in bladder cancer , 2007, International journal of cancer.

[14]  V. Reuter,et al.  Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma , 2006, Clinical Cancer Research.

[15]  A. Sabichi,et al.  Clinical model of lifetime cost of treating bladder cancer and associated complications. , 2006, Urology.

[16]  M. Pierotti,et al.  MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Simpson,et al.  Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[18]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[19]  M. Maio,et al.  Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine , 2004, Cancer Research.

[20]  V. Reuter,et al.  Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. , 2003, Cancer immunity.

[21]  E. Sabo,et al.  Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Yao-Tseng Chen,et al.  Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. , 2001, Cancer research.

[23]  F. Algaba,et al.  Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. , 2000, The Journal of urology.

[24]  J. Patard,et al.  Expression of mage genes in transitional‐cell carcinomas of the urinary bladder , 1995, International journal of cancer.

[25]  T. Boon,et al.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Bruggen,et al.  The CD 4 + T-Cell Response of Melanoma Patients to a MAGE-A 3 Peptide Vaccine Involves Potential Regulatory T Cells , 2009 .

[27]  L. Old,et al.  Cancer vaccines: an overview. , 2008, Cancer immunity.

[28]  Y. Doki,et al.  T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. , 2007, Cancer immunity.

[29]  Y. Horiguchi,et al.  Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  G. Hermann,et al.  The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. , 1998, The Journal of urology.